August 10, 2017 / 3:55 PM / in 2 months

BRIEF-Odiparcil awarded Orphan Drug Designation by the FDA

Aug 10 (Reuters) - INVENTIVA SA:

* INVENTIVA: ODIPARCIL AWARDED ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF MPS VI BY THE FDA

* ODIPARCIL AWARDED ORPHAN DRUG DESIGNATION FOR TREATMENT OF MPS VI BY FDA

* MPS VI (MAROTEAUX-LAMY SYNDROME), IS A RARE PEDIATRIC GENETIC DEGENERATIVE DISEASE

* FIRST PATIENT ENROLLMENT IN A PHASE IIA STUDY EXPECTED BY YEAR-END 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below